Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00469183 · ClinicalTrials.gov registry record · Phase 4
Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 70
- Enrollment target
NCT00469183 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 70 participants.
The verdict
NCT00469183, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 70 participants
- Enrollment target
Study Summary
Evaluate atrophogenic potential of long-term use of Tri-Luma Cream on facial Melasma through biopsy examination.
Interventions
- DRUG Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00469183
The ClinicalTrials.gov registry entry for NCT00469183 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05% is the first listed.
NCT00469183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00469183 about?
NCT00469183 is a clinical study titled "Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma". Evaluate atrophogenic potential of long-term use of Tri-Luma Cream on facial Melasma through biopsy examination.
What is the current status of trial NCT00469183?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2006-05. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00469183?
The interventions under investigation include: Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05% (DRUG).
Who is sponsoring clinical trial NCT00469183?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.